![Cabazitaxel [Jevtana] – (Chemotherapy for Advanced Prostate Cancer)](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E)
Introduction
Cabazitaxel, sold under the trade name Jevtana, is a chemotherapy medication used to treat advanced prostate cancer that has progressed after treatment with docetaxel. It is particularly effective in castration-resistant prostate cancer (CRPC), offering another option for patients with limited therapeutic choices.
Purpose
- Treats metastatic castration-resistant prostate cancer (mCRPC).
- Effective in patients who have not responded to or have progressed after docetaxel treatment.
How It Works
Cabazitaxel is a taxane derivative that disrupts microtubule function during cell division, leading to cancer cell death. Its structure allows it to overcome some resistance mechanisms that limit the effectiveness of docetaxel.
Usage
- Administered as an intravenous (IV) infusion, typically every three weeks.
- Often combined with prednisone to enhance efficacy and reduce side effects.
- Pre-medication with antihistamines, corticosteroids, and antiemetics is recommended to prevent hypersensitivity reactions.
Considerations
- Common side effects include fatigue, nausea, hair loss, and diarrhea.
- Serious risks include neutropenia, febrile neutropenia, and hypersensitivity reactions.
- Close monitoring is essential, including blood counts and liver function tests.
At Crossroads Urology
At Crossroads Urology, Cabazitaxel is part of our comprehensive approach to managing advanced prostate cancer. We collaborate with oncology teams to provide personalized care, ensuring patients achieve the best possible outcomes.
Conclusion
Cabazitaxel [Jevtana] offers hope for patients with advanced prostate cancer who have progressed on prior treatments. Contact Crossroads Urology today to learn how this therapy can be part of your cancer care plan.
